Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals (OTCQB: AGNPF), has appointed Netcapital Securities for its planned Regulation A offering. The company has filed Form 1-A with the SEC, though the offering hasn't been qualified yet.
The proceeds will fund a Phase 2a DMT study involving 40 stroke patients, scheduled for Q3 2025 in Hungary. The study will be led by Dr. Sándor Nardai at the National Institute of Mental Health, Neurology and Neurosurgery in Budapest.
Additionally, the company granted 1,405,000 restricted share units (RSUs) and 1,000,000 stock options at $0.09, exercisable for five years, to executives and directors. Both RSUs and options vest immediately upon grant.
Algernon NeuroScience, una filiale di Algernon Pharmaceuticals (OTCQB: AGNPF), ha nominato Netcapital Securities per la sua offerta pianificata secondo la Regola A. L'azienda ha presentato il modulo 1-A alla SEC, anche se l'offerta non è ancora stata qualificata.
I proventi finanzieranno uno studio DMT di Fase 2a che coinvolgerà 40 pazienti colpiti da ictus, previsto per il terzo trimestre del 2025 in Ungheria. Lo studio sarà guidato dal Dr. Sándor Nardai presso l'Istituto Nazionale di Salute Mentale, Neurologia e Neurochirurgia di Budapest.
Inoltre, l'azienda ha concesso 1.405.000 unità azionarie vincolate (RSU) e 1.000.000 opzioni su azioni a $0,09, esercitabili per cinque anni, a dirigenti e membri del consiglio. Sia le RSU che le opzioni maturano immediatamente al momento della concessione.
Algernon NeuroScience, una subsidiaria de Algernon Pharmaceuticals (OTCQB: AGNPF), ha nombrado a Netcapital Securities para su oferta planificada de Regulación A. La compañía ha presentado el formulario 1-A a la SEC, aunque la oferta aún no ha sido calificada.
Los ingresos financiarán un estudio DMT de Fase 2a que involucrará a 40 pacientes con accidente cerebrovascular, programado para el tercer trimestre de 2025 en Hungría. El estudio será dirigido por el Dr. Sándor Nardai en el Instituto Nacional de Salud Mental, Neurología y Neurocirugía en Budapest.
Además, la compañía otorgó 1.405.000 unidades de acciones restringidas (RSUs) y 1.000.000 opciones sobre acciones a $0.09, ejercitables durante cinco años, a ejecutivos y directores. Tanto las RSUs como las opciones se consolidan inmediatamente al momento de la concesión.
알저넌 뉴로사이언스, 알저넌 제약(OTCQB: AGNPF)의 자회사, 는 계획된 규정 A 제공을 위해 넷캐피탈 증권을 임명했습니다. 이 회사는 SEC에 1-A 양식을 제출했지만, 제공은 아직 승인되지 않았습니다.
수익금은 2025년 3분기에 헝가리에서 40명의 뇌졸중 환자를 대상으로 하는 2a 단계 DMT 연구에 사용될 예정입니다. 이 연구는 부다페스트에 있는 국립정신건강신경과 신경외과 연구소의 Sándor Nardai 박사가 이끌 것입니다.
또한, 이 회사는 경영진과 이사에게 1,405,000개의 제한 주식 단위(RSU)와 1,000,000개의 주식 옵션을 $0.09에 부여했으며, 이는 5년 동안 행사할 수 있습니다. RSU와 옵션 모두 부여 시 즉시 발생합니다.
Algernon NeuroScience, une filiale d'Algernon Pharmaceuticals (OTCQB: AGNPF), a nommé Netcapital Securities pour son offre prévue selon la réglementation A. L'entreprise a déposé le formulaire 1-A auprès de la SEC, bien que l'offre n'ait pas encore été qualifiée.
Les recettes financeront une étude DMT de Phase 2a impliquant 40 patients victimes d'accidents vasculaires cérébraux, prévue pour le troisième trimestre de 2025 en Hongrie. L'étude sera dirigée par le Dr Sándor Nardai à l'Institut National de la Santé Mentale, de la Neurologie et de la Neurochirurgie à Budapest.
De plus, l'entreprise a accordé 1.405.000 unités d'actions restreintes (RSUs) et 1.000.000 options d'achat d'actions au prix de 0,09 $, exerçables pendant cinq ans, à des dirigeants et des administrateurs. Les RSUs et les options deviennent immédiatement acquises lors de l'octroi.
Algernon NeuroScience, eine Tochtergesellschaft von Algernon Pharmaceuticals (OTCQB: AGNPF), hat Netcapital Securities für ihr geplantes Angebot gemäß Regulation A beauftragt. Das Unternehmen hat das Formular 1-A bei der SEC eingereicht, obwohl das Angebot noch nicht genehmigt wurde.
Die Einnahmen werden eine Phase 2a DMT-Studie finanzieren, an der 40 Schlaganfallpatienten teilnehmen, die für das 3. Quartal 2025 in Ungarn geplant ist. Die Studie wird von Dr. Sándor Nardai am Nationalen Institut für Psychische Gesundheit, Neurologie und Neurochirurgie in Budapest geleitet.
Darüber hinaus hat das Unternehmen 1.405.000 eingeschränkte Aktieneinheiten (RSUs) und 1.000.000 Aktienoptionen zu einem Preis von 0,09 $ vergeben, die fünf Jahre lang ausgeübt werden können, an Führungskräfte und Direktoren. Sowohl RSUs als auch Optionen werden sofort bei der Gewährung fällig.
- Advancing to Phase 2a clinical trial for DMT stroke treatment
- Partnership with established broker-dealer Netcapital Securities
- Study led by leading European stroke expert
- Potential shareholder dilution from RSUs and stock options grant
- Reg A offering not yet qualified by SEC
- Additional capital needed to fund operations
VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary Algernon NeuroScience (AGN Neuro), has appointed Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer, for its planned Regulation A (Reg A) offering. Netcapital plans to provide broker-dealer and administrative services, excluding underwriting and placement agent services, in connection with this offering.
AGN Neuro has filed a Form 1-A with the U.S. Securities and Exchange Commission (SEC), though the offering has not yet been qualified or declared effective by the SEC. AGN Neuro intends to use proceeds from the offering to advance its R&D initiatives, including conducting a randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 actual stroke patients in the third quarter of 2025 in Hungary. The Principal Investigator of the study will be Dr. Sándor Nardai of the National Institute of Mental Health, Neurology and Neurosurgery in Budapest, one of Europe’s leading stroke experts.
“We are pleased that Algernon NeuroScience has selected Netcapital Securities as its broker-dealer to provide critical compliance and operational support for this offering,” said Martin Kay, CEO at Netcapital Inc.
“We look forward to working with the team at Netcapital Securities as we advance through the SEC qualification process for our planned Reg A offering,” said Christopher J. Moreau, CEO of Algernon NeuroScience.
The securities referenced in the planned Reg A offering may not be sold, nor may offers to buy be accepted, before the offering statement filed with the SEC is qualified. This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offers, solicitations, or sales of securities will be made only by means of an offering circular that meets the requirements of Regulation A.
No money or other consideration is being solicited at this time, and if sent in response, it will not be accepted. There is no assurance that the SEC will qualify the offering or that Algernon NeuroScience will successfully raise capital. Investing in early-stage companies involves significant risks, and prospective investors should carefully review all offering materials and risk disclosures before making an investment decision.
The Company also announces a grant of 1,405,000 restricted share units pursuant to its RSU Plan (each, an "RSU") to certain executives and directors, of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent of one common share of the Company on vesting. The RSUs vest on the date of grant.
The Company has also granted 1,000,000 stock options exercisable at
The Company’s
The RSUs and stock options are subject to approval by regulatory authorities.
About Netcapital Inc.
Netcapital Inc. is a fintech company with a scalable technology platform that allows private companies to raise capital online and provides private equity investment opportunities to investors. The Company's consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies. The Company’s funding portal, Netcapital Funding Portal, Inc., is registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”), a registered national securities association. The Company’s broker-dealer, Netcapital Securities Inc., is also registered with the SEC and is a member of FINRA.
About Algernon NeuroScience Inc.
Algernon NeuroScience is a wholly-owned private subsidiary of Algernon Pharmaceuticals and has been established to advance its DMT program for stroke and traumatic brain injury (TBI). For more information, visit https://algernonneuroscience.com.
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a Canadian clinical stage pharmaceutical development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is also the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. For more information visit www.algernonpharmaceuticals.com.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 Ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the closing of a private placement, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is the purpose of Algernon NeuroScience's (AGNPF) Regulation A offering?
How many RSUs and stock options did AGNPF grant in March 2025?
Who will lead AGNPF's Phase 2a DMT stroke study in Hungary?
What is the vesting schedule for AGNPF's newly granted RSUs and options?
